China Heart Failure Registry Study——A Multicenter, Prospective Investigation for Preliminary Analysis on Etiology, Clinical Features and Treatment in Heart Failure Patients
10.3969/j.issn.1000-3614.2015.05.002
- VernacularTitle:多中心、前瞻性中国心力衰竭注册登记研究——病因、临床特点和治疗情况初步分析
- Author:
Jian ZHANG
;
Yuhui ZHANG
- Publication Type:Journal Article
- Keywords:
Heart failure;
Case features;
Treatment
- From:
Chinese Circulation Journal
2015;30(5):413-416
- CountryChina
- Language:Chinese
-
Abstract:
Objective: China Heart Failure Registry Study (China-HF) is aimed to understand the etiology, clinical features and treatment of in-hospital heart failure (HF) patients in China. Methods: Based on geographic region and economic condition, we prospectively recruited the in-hospital patients with primarily diagnosed HF, and the demographic information, etiology, clinical features and treatment condition were collected by electronic case report form in all patients. Results: A total of 8516 HF patients from 88 participating hospitals between 2012-01 and 2014-12 were analyzed. The average age of patients was at 66 years with 54.5% male. There were 6777/7997 (84.7%) patients with NYHA functional classiifcation at III-IV, 4207/8516 (49.4%) with coronary artery disease (CAD), 4649 (54.6%) with hypertension, 2109/7102 (29.7%) with chronic kidney disease and 2478/6608 (37.5%) with left ventricular ejection fraction (LVEF) < 40%. The patients with infection 3909/8516 (45.9%) and exertion or stress 2214 (26.0%) and myocardial ischemia 1967 (23.1%) were the major cause of HF worsening. There were 6165/8516 (72.4%) patients treated by intravenous diuretics during hospitalization, and after discharge, 5722 (67.2%) patients received oral loop diuretics, 2563 (30.1%) received angiotensin converting enzyme inhibitor, 2095 (24.6%) received angiotensin II receptor antagonist. The median length of in-hospital stay was 11 days and the in-hospital mortality was 5.3% (451/8516). Conclusion: China-HF provides a comprehensive insight of clinical features for the in-hospital HF patients in China. There is still a gap for medications between our current condition and the guideline, it is important to educate both patients and physicians in clinical practice.
